ADRs Close Lower; RedHill Biopharma Rises
ADRs Close Lower; RedHill Biopharma Rises
DJ ADRs Close Lower; RedHill Biopharma Rises
DJ ADR收盤走低；Redhill Biophma上漲
International stocks trading in New York closed lower on Monday.
在紐約交易的國際股市週一收跌。
The S&P/BNY Mellon index of American depositary receipts fell 1.1% to 157.34. The European index declined 0.3% to 140.16. The Asian index fell 2.2% to 209.35. The Latin American index declined 1.7% to 186.46. And the emerging-markets index fell 2.1% to 344.21.
S&P/紐約梅隆美國存託憑證指數跌1.1%，報157.34點。歐洲指數下跌0.3%，至140.16點。亞洲指數跌2.2%，報209.35點。拉丁美洲指數下跌1.7%，至186.46。新興市場指數下跌2.1%，至344.21點。
RedHill Biopharma Ltd. was among the companies whose ADRs traded actively.
Redhill Biophma有限公司是美國存託憑證交易活躍的公司之一。
A group of oil producers plans to lift its collective output by 400,000 barrels a day in monthly installments, part of a previously agreed plan to return output to pre-Covid-19 levels. OPEC+, which includes members of the Organization of the Petroleum Exporting Countries and others led by Russia, decided against opening the taps more widely, driving U.S. crude prices to their highest levels since 2014. BP PLC rose 1.5% to $28.01; Eni Spa roes 1% to $27.11; Royal Dutch Shell PLC's Class B ADRs rose 1% to $45.38; and TotalEnergies SE improved 1.3% to $48.67.
一批產油國計劃按月分期付款將日總產量提高40萬桶，這是此前達成的將產量恢復到新冠肺炎之前水平的計劃的一部分。包括石油輸出國組織(Organization of the Petroleum Exporting Countries，簡稱歐佩克)成員國和以俄羅斯為首的其他國家在內的歐佩克+決定不更大範圍地打開水龍頭，將美國原油價格推高至2014年以來的最高水平。英國石油公司(BP PLC)上漲1.5%，至28.01美元；埃尼集團(Eni Spa)股價上漲1%，至27.11美元；荷蘭皇家殼牌石油公司-B的B類美國存託憑證(ADR)上漲1%，至45.38美元；道達爾上漲1.3%，至48.67美元。
RedHill Biopharma Ltd.'s ADRs closed 12% higher at $4.88 after the company said it had new data from a Phase 2/3 clinical study evaluating its experimental oral antiviral opaganib in severely ill, hospitalized Covid-19 patients, MarketWatch reported. RedHill said the treatment candidate reduced mortality by 62% when evaluating 251 of the 475 patients enrolled in the study.
據MarketWatch報道，Redhill Biophma Ltd.的ADRS收盤上漲12%，至4.88美元，此前該公司表示，其2/3期臨牀研究獲得了新數據，該研究評估了其針對住院重症患者的實驗性口服抗病毒奧帕尼布(Opaganib)。Redhill説，在評估參與該研究的475名患者中的251名時，該候選藥物的死亡率降低了62%。
(END) Dow Jones Newswires
(完)道瓊通訊社
October 04, 2021 18:09 ET (22:09 GMT)
2021年10月4日18：09美國東部時間(格林尼治標準時間22：09)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司